KGH Becomes First Government Hospital in Andhra Pradesh to Offer Free Immunotherapy for Stage IV Lung Cancer Patients
核心洞察
King George Hospital (KGH) (搜索) in Visakhapatnam has launched a clinical trial providing free immunotherapy (搜索) combined with chemotherapy to Stage IV lung cancer (搜索) patients, becoming the first government hospital in Andhra Pradesh to do so.
Eligible patients aged 16–65 years (or 18–65 per alternate source) will receive 17 cycles of immunotherapy (搜索) over one year, with each cycle valued at approximately ₹4 lakh in the private sector.
Dr. K. Shilpa, Head of Medical Oncology, serves as principal investigator, with KGH Superintendent Dr. I. Vani highlighting the initiative's role in improving access for financially constrained patients.
The Oncology Department of King George Hospital (KGH) (搜索) in Visakhapatnam has launched a landmark clinical trial offering free immunotherapy (搜索) to patients diagnosed with Stage IV lung cancer (搜索), marking the first time a government hospital in Andhra Pradesh has provided such advanced treatment at no cost.
KGH Superintendent Dr. I. Vani announced that the hospital is currently the only government cancer centre in the state conducting this clinical trial. "Lung cancer remains one of the leading causes of cancer-related deaths worldwide, and immunotherapy (搜索) has emerged as an important treatment option for certain categories of advanced-stage patients. However, the high cost of treatment has often limited access, particularly in the public healthcare system," she explained.
Trial Design and Patient Eligibility
The clinical trial, conducted by the Department of Medical Oncology, will provide immunotherapy (搜索) in combination with chemotherapy to eligible patients over a one-year period. According to hospital authorities, a single cycle of the immunotherapy drug costs approximately ₹4 lakh in the private sector. Under the trial, patients will receive one dose every three weeks, totaling 17 cycles over the course of a year, entirely free of charge.
Eligibility criteria specify patients diagnosed with Stage IV lung cancer (搜索). One source indicates the age range as 16 to 65 years, while another cites 18 to 65 years. Dr. I. Vani urged eligible patients to approach the hospital and enroll in the programme after medical evaluation.
Leadership and Clinical Oversight
Dr. K. Shilpa, Head of the Medical Oncology Department at KGH, will serve as the principal investigator for the clinical trial, overseeing its execution and ensuring adherence to protocol.
Addressing Access Barriers in Public Healthcare
The initiative directly targets the financial inaccessibility that has historically prevented many patients in the public healthcare system from receiving immunotherapy (搜索). Dr. Vani emphasized that the programme would help patients who may otherwise find such treatment financially out of reach.
Beyond immediate patient care, the clinical trial is expected to provide eligible patients access to newer treatment options while contributing to ongoing research in cancer care, potentially generating valuable data on immunotherapy (搜索) outcomes in the Indian public healthcare setting.